Characteristics of patients diagnosed with NHL during prospective follow-up according to whether they had initiated HAART
| . | All patients (n = 222) . | NHL pre-HAART (n = 125) . | NHL post-HAART (n = 97) . | P3-150 . |
|---|---|---|---|---|
| Subtype of NHL, % Burkitt/immunoblastic/ PBL/other/unknown histology | 9/28/34/28 | 10/27/38/25 | 7/30/16/46 | < .001 |
| Method of diagnosis, definitive/presumptive/autopsy | 7813/9 | 71/16/13 | 87/8/5 | .022 |
| Sex, % female | 16.7 | 20.0 | 12.4 | .13 |
| HIV transmission group | .007 | |||
| Homosexual, % | 51.4 | 53.6 | 48.5 | |
| Intravenous drug use, % | 20.7 | 26.4 | 13.4 | |
| Heterosexual, % | 20.6 | 15.2 | 29.2 | |
| Race, % Caucasian | 92.3 | 96.0 | 87.6 | .020 |
| AIDS diagnosis before NHL, % | 63.1 | 67.2 | 57.7 | .15 |
| Antiretroviral treatment experienced, % | 95.3 | 92.0 | 100.0 | .003 |
| Ever exposed to PI/NNRTI, % | 44.6 | 5.6 | 94.9 | < .001 |
| Age, y, median (IQR) | 40 (34-48) | 38 (34-45) | 42 (34-51) | .010 |
| CD4 count, cells/mm3, median (IQR) | 50 (12-163) | 30 (8-82) | 108 (33-223) | < .001 |
| Plasma viral load, log10 copies/mL, median (IQR) | 4.3 (2.8-5.4) | 5.0 (4.6-5.9) | 4.0 (2.7-5.2) | .010 |
| . | All patients (n = 222) . | NHL pre-HAART (n = 125) . | NHL post-HAART (n = 97) . | P3-150 . |
|---|---|---|---|---|
| Subtype of NHL, % Burkitt/immunoblastic/ PBL/other/unknown histology | 9/28/34/28 | 10/27/38/25 | 7/30/16/46 | < .001 |
| Method of diagnosis, definitive/presumptive/autopsy | 7813/9 | 71/16/13 | 87/8/5 | .022 |
| Sex, % female | 16.7 | 20.0 | 12.4 | .13 |
| HIV transmission group | .007 | |||
| Homosexual, % | 51.4 | 53.6 | 48.5 | |
| Intravenous drug use, % | 20.7 | 26.4 | 13.4 | |
| Heterosexual, % | 20.6 | 15.2 | 29.2 | |
| Race, % Caucasian | 92.3 | 96.0 | 87.6 | .020 |
| AIDS diagnosis before NHL, % | 63.1 | 67.2 | 57.7 | .15 |
| Antiretroviral treatment experienced, % | 95.3 | 92.0 | 100.0 | .003 |
| Ever exposed to PI/NNRTI, % | 44.6 | 5.6 | 94.9 | < .001 |
| Age, y, median (IQR) | 40 (34-48) | 38 (34-45) | 42 (34-51) | .010 |
| CD4 count, cells/mm3, median (IQR) | 50 (12-163) | 30 (8-82) | 108 (33-223) | < .001 |
| Plasma viral load, log10 copies/mL, median (IQR) | 4.3 (2.8-5.4) | 5.0 (4.6-5.9) | 4.0 (2.7-5.2) | .010 |
P is derived from a comparison between the pre-HAART and post-HAART group.